PAI Pharma Buys Nexus Pharmaceuticals, Adding 20-Plus Hospital Injectables

PAI Pharma has acquired Nexus Pharmaceuticals, a deal that adds more than 20 commercial hospital injectable products to the buyer's portfolio, according to the acquisition announcement.

The transaction also brings Nexus's customer relationships and pharmaceutical development expertise into PAI's growing sterile pharmaceutical business. PAI, a portfolio company of private equity firm Olympus Partners, develops, manufactures and markets oral liquid medicines, ready-to-use sterile injectables and other hospital-focused products from its headquarters in Parsippany, New Jersey.

The numbers tell the strategy plainly: two acquisitions — Nexus now, Nivagen before it — building one hospital pharmaceutical platform.

What does the acquisition add?

Nexus specializes in complex injectable products, including therapies that have historically experienced supply shortages. The announcement describes a business that combines pharmaceutical development and analytical capabilities with contract manufacturing relationships and established U.S. hospital customers.

Those capabilities complement what PAI already sells: ready-to-dose oral liquid products and an expanding sterile injectable offering. The deal broadens both the range of medicines PAI can offer and the commercial relationships through which it reaches healthcare providers.

The takeaway: PAI didn't just buy products — it bought a route into hospital customers that already depend on hard-to-source injectables.

Why pair Nexus with Nivagen?

The Nexus purchase follows PAI's acquisition of Nivagen, which added aseptic manufacturing capabilities in Sacramento. Together, the transactions support PAI's strategy of building a broader essential medicines portfolio and increasing its presence in hospital markets, the announcement states.

The two deals bring different capabilities to the combined platform. Nivagen contributes production capacity. Nexus contributes development and commercialization experience.

PAI identified domestic manufacturing investment as an important part of that strategy. The company serves customers requiring oral liquid, sterile and ready-to-use dosage forms, and the Nexus transaction continues its effort to combine those categories within a larger hospital-oriented pharmaceutical business.

In plain words: one deal built the factories, this one fills them with products and customers.

Who advised on the deal?

William Blair served as PAI's exclusive financial advisor, while Kirkland & Ellis provided legal counsel to PAI. Proskauer Rose served as legal counsel to Nexus.

The announcement did not disclose the purchase price or expected closing terms.

What it means for hospital supply

The announcement centers on portfolio expansion and complementary capabilities. The acquired injectable products add to PAI's existing manufacturing and commercialization activities across critical care, oncology and other hospital settings.

For a buyer whose parent, Olympus Partners, is bankrolling a rollup of essential medicines, the logic is consolidation: more hospital products, more dosage forms, more U.S. manufacturing under one roof.

The so-what for providers: a larger, domestically anchored supplier of injectables that have historically run short could matter the next time a shortage hits — if PAI executes on the combined platform it has now assembled.